Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | Promise of exosomal proteins as biomarkers in Alzheimer’s disease

Exosomal proteins are well studied in the context of cancer, but have been somewhat overlooked in terms of neurodegeneration. Charisse Winston, PhD, University of California San Diego, La Jolla, CA, explains that the types and levels of cargo within extracellular vesicles can change across different stages of Alzheimer’s disease (AD). Cargos such as amyloid, tau, and synaptic markers are of interest, and current research is investigating the varying levels and profiles of cargo and how this relates to disease state. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.